Marklund Marie, Franklin Karl A
Department of Orthodontics, University Hospital, Umeå, Sweden.
J Sleep Res. 2007 Dec;16(4):414-20. doi: 10.1111/j.1365-2869.2007.00615.x.
Mandibular repositioning appliances (MRAs) reduce symptoms of obstructive sleep apnoea in the short term, but the long-term effects are unknown. Our objective was to evaluate the long-term symptomatic effects of custom-made MRAs and to identify the patients who will experience subjective benefits from treatment. A cohort of 260 consecutive patients treated with appliances for non-apnoeic snoring or sleep apnoea was followed up by a questionnaire and examination after an average of 5.4 years. The subjective effect was defined as good when complaints of daytime sleepiness occurred less than once a week. A total of 185 patients (71%) responded to the questionnaires. Of the respondents, 96 reported frequent use, 33 reported infrequent use, 26 reported discontinued treatment and 30 reported modified treatment. Mild cases (apnoea-hypopnoea index [AHI] < 15) were likelier than more severe cases to continue treatment. Patients who had used MRAs reported fewer complaints of sleepiness, headaches and daytime naps. Frequent use (P = 0.001), few night-time awakenings before start of treatment (P = 0.02) and effective apnoea reduction during treatment of more severe cases (P = 0.02) correlated with a good subjective effect at long-term follow-up. Our conclusion is that custom-made MRAs reduce sleep apnoea symptoms in the long term. The mildest cases will experience the greatest long-term benefit. The reason is that non-apnoeic snorers and patients with a mild disease are more likely to continue treatment and that their long-term results with regard to excessive sleepiness are similar to patients with a more severe disease.
下颌重新定位矫治器(MRAs)在短期内可减轻阻塞性睡眠呼吸暂停的症状,但长期效果尚不清楚。我们的目的是评估定制MRAs的长期症状效果,并确定能从治疗中获得主观益处的患者。通过问卷调查和检查,对260例连续接受矫治器治疗非呼吸暂停性打鼾或睡眠呼吸暂停的患者进行了平均5.4年的随访。当白天嗜睡的主诉每周少于一次时,主观效果被定义为良好。共有185例患者(71%)回复了问卷。在回复者中,96例报告经常使用,33例报告偶尔使用,26例报告停止治疗,30例报告改变治疗方式。轻度病例(呼吸暂停低通气指数[AHI]<15)比重度病例更有可能继续治疗。使用过MRAs的患者报告的嗜睡、头痛和白天打盹的主诉较少。经常使用(P = 0.001)、治疗开始前夜间觉醒次数少(P = 0.02)以及重度病例治疗期间呼吸暂停有效减少(P = 0.02)与长期随访时良好的主观效果相关。我们的结论是,定制MRAs可长期减轻睡眠呼吸暂停症状。最轻度的病例将获得最大的长期益处。原因是,非呼吸暂停性打鼾者和轻度疾病患者更有可能继续治疗,而且他们在过度嗜睡方面的长期结果与重度疾病患者相似。